Medical Device News Magazine

Akadeum Life Sciences Announces Two New Microbubble Kits at Advanced Therapies Week

he Human T Cell Selection, Activation, and Expansion and Human T Cell Depletion kits use Akadeum’s BACS(TM) microbubbles to streamline cell therapy workflows.

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Akadeum Life Sciences

Today, Akadeum Life Sciences, the market leader in buoyancy-based cell separation is announcing the release of a Human T Cell Selection, Activation, and Expansion Kit (GMP Grade), and a Human T Cell Depletion Kit (GMP Grade) at the Advanced Therapies Week on Jan 16. The kits add to Akadeum’s market-leading product portfolio in flotation-based technology, taking the company’s products one step further toward clinical trials.

2024 CAR T Cell Therapy Cost

In 2024, CAR T cell therapy can cost anywhere between $500,000 and $1 million per patient, predominantly because of the steep expense that existing manufacturing processes like magnets and columns require. The Human T Cell Selection, Activation, and Expansion and Human T Cell Depletion kits will provide CDMOs, cell and gene therapy companies, and researchers the improved cell therapy workflows and cost-savings that existing methods of cell separation cannot provide.

Unlike microbubbles, magnetic beads and columns are limited in their selection capacity and can damage more sensitive cell types, potentially decreasing cell viability and risking population integrity.

The Human T Cell Selection, Activation, and Expansion kit

The Human T Cell Selection, Activation, and Expansion kit isolates and extracts highly pure populations of T cells and activates them for use in cell therapy workflows. By mixing the product into a sample, microbubbles positively select and bind to cells expressing CD3 and CD28, gently floating them to the surface of the mixture. The kit beats the efficiency of magnetic methods of selection, activation, and expansion by providing reduced cell exhaustion, increased numbers of activated T cell populations, and a highly scalable solution that fits into a variety of cell therapy workflows.

The Human T Cell Depletion Kit

The Human T Cell Depletion kit removes non-gene-edited cells from CAR T manufacturing cultures. The product positively selects unwanted T cells, leaving a highly pure and untouched sample of engineered cells ready for downstream formulation. The robust depletion kit allows for the increased recovery of gene-edited cells and maintains the improved health of the cell therapy product.

Casey Wegner, Vice President of R&D at Akadeum comments…

“Our innovative new GMP-compliant separation kits not only yield an unparalleled number of healthy cells, but provide a quicker and more cost-effective solution, expanding the horizon of possibility for researchers currently limited by time and cost constraints.”

“Cell and gene therapy companies utilizing magnetic beads and columns in their workflows will now be at a competitive disadvantage. Harnessing the power of gravity, Akadeum’s eco-friendly, gentle flotation technology rapidly produces healthy cells, empowering researchers to increase the accessibility and efficiency of CAR T cell therapy.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”